HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
10.28
+0.16 (1.58%)
At close: Jun 18, 2026, 4:00 PM EDT
10.39
+0.11 (1.07%)
After-hours: Jun 18, 2026, 5:05 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
$305,408
Profits / Employee
$254,404
Market Cap
1.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,475 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
HCM News
- 3 days ago - Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PRNewsWire
- 3 days ago - isolved Honors Top-Performing Partners at Annual Connect for Partners Event - GlobeNewsWire
- 4 days ago - isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees - GlobeNewsWire
- 4 days ago - Paychex Recognized as a Top WorkTech Company by TIME - GlobeNewsWire
- 7 days ago - HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewsWire
- 4 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 4 weeks ago - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - GlobeNewsWire
- 4 weeks ago - Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - PRNewsWire